Cerises 🇨🇵 (@Moooonflash) header
Cerises 🇨🇵 (@Moooonflash) profile picture

🇲🇫 🪆 IT business analyst + artist before 🦠 #LongCovid : #fibrosis #neuropathy #SFN #MCAS #MRGPRX2 SARS-COV-2 = persistent vascular virus

France
Joined May 2022
Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)Photo by Cerises 🇨🇵 (@Moooonflash)
Antivirals (taken in first hours after infection or symptoms) are the only thing that can prevent #LongCovid . If false or not efficient paths are taken for the cure of Long Covid, we will forever be at risk of several cumulative #LongCovid
7
8
4
59
11,026
#LongCOVID #biomarkers At the 4th International Long COVID Conference, ANRS MIE and the “Long COVID” coordinated action organized a symposium on potential biomarkers of Long COVID. 👉 Discover French studies supported by ANRS MIE anrs.fr/en/all-news/long-cov… #LongCOVIDIntl
1
10
1
18
736
🧵🌍 L’OMS Europe lance un guide destiné à former les personnels de santé aux spécificités du #CovidLong chez les adultes mais aussi les enfants.
1
6
1
15
559
Cerises 🇨🇵 retweeted
Leeds Children’s Hospital studied 199 children and found a 43% rise in autoimmune liver disease diagnoses after the pandemic began, particularly autoimmune hepatitis. Researchers suspect viral infections may trigger immune dysregulation. onlinelibrary.wiley.com/doi/…
5
80
2
214
4,759
Cerises 🇨🇵 retweeted
University of Melbourne researchers studied 481 hospitalized COVID-19 patients and found antibodies helping immune cells clear infected cells were linked to lower viral loads and better outcomes. Adding hyperimmune IVIG showed no clinical benefit. academic.oup.com/jid/advance…
10
1
25
799
Cerises 🇨🇵 retweeted
⚫️L'ancien député Raphaël Gérard (LREM) est décédé dimanche à l'âge de 58 ans. Atteint d'un Covid long dont il gardait des séquelles, il avait témoigné dans l'hémicycle de l'Assemblée en 2022 sur les "30 centimètres de câbles et trois kilos de matériel que je porte vingt-quatre heures sur vingt-quatre"
289
543
74
1,688
270,105
Cerises 🇨🇵 retweeted
UC Berkeley researchers found that a SARS-CoV-2 protein called PLpro directly activates sensory neurons through TRPA1, triggering sneezing, coughing, and pain in mice. The findings, also tested in human neurons, reveal a new mechanism of viral symptoms. cell.com/neuron/fulltext/S08…
2
26
1
75
2,676
Cerises 🇨🇵 retweeted
We'll be seeing a lot more of this. @katiebindley's diagnosis experience gift link wsj.com/health/wellness/how-…
15
69
9
302
43,127
Cerises 🇨🇵 retweeted
Institut Cochin researchers studied over 100 Long COVID patients. They reported infectious SARS-CoV-2 in platelets derived from megakaryocytes. In laboratory experiments, these platelets transmitted infection to macrophages.
4
45
3
317
15,233
Cerises 🇨🇵 retweeted
The 4th Long COVID International Conference just concluded in Nice, France. These findings are from conference abstracts, many awaiting full publication, peer review, and independent replication. Here’s the emerging pathobiology that caught my attention. 🧵
35
650
61
1,765
103,324
Cerises 🇨🇵 retweeted
non alcoholic fatty liver disease is skyrocketing thanks to covid infections! confirmed by my cardiologist who also keeps up with covid research
grade 1 fatty liver without consuming a drop of alcohol 🥲
22
521
14
2,789
60,222
💯💥🎯
We are still in the Stone Age when 99% of physicians don’t realize symptoms are from chronic infections.
1
73
Cerises 🇨🇵 retweeted
🧠🔬Cette 4e Conférence internationale sur le #CovidLong s'achève sur une belle richesse de connaissances, de réflexions et de perspectives pour la recherche. 👇
2
11
36
662
Cerises 🇨🇵 retweeted
Cambridge researchers got the heart to grow back muscle after a heart attack. Adult heart muscle cells stop multiplying shortly after birth, so the cells that die in a heart attack (up to a billion in humans) are never replaced. A short mRNA injection switched that ability back on in mice. - The mRNA briefly turns on two proteins in the heart cells, Myc and Cyclin T1. - Blood pumped per heartbeat went up by around 10%, and the effect was still there after 12 weeks. Published in Nature Cardiovascular Research. A heart that repairs itself, that's the holy grail of cardiology. Beside all the sad news about NVIDIA, this gives so much hope!
34
52
6
757
25,976
Cerises 🇨🇵 retweeted
I'm a doctor. A deep subspecialist. If you have unexplained symptoms, or a diagnosis where the treatment isn't working, upload ALL your records into a frontier LLM. Tell it not to just agree with you. Suggested prompt in first reply. This WSJ story about a "medical mystery" solved by AI after decades of specialists missed it? It's not rare. It's not even uncommon. It might be the norm. I see it literally all the time. Sometimes I'm the specialist who missed it. At reading your whole history and connecting the dots across it, any frontier AI is WAY better than your doctors. None of us ever has time to read the whole chart. I strongly recommend Claude, but any frontier model works. Set it to the highest reasoning and effort. Tell it to ask you every question it needs answered. Tell it you know it can't diagnose you, and your goal is the most likely differential diagnosis and a one-page summary with its rationale. Take that to your doctor. If they don't take it seriously, find a new doctor.
After years of suffering from perplexing symptoms, WSJ’s Katherine Bindley turned to AI—and finally got answers to the complex condition her doctors had overlooked. Read more: 🔗 mrf.lu/27KSt
48
65
14
644
141,393
Cerises 🇨🇵 retweeted
Some incredible science coming out of the Long COVID conference in France this week. Viral persistence, autoimmunity, immune dysregulation, biomarkers, and clinical trials. It’s crazy how far this field has come in just five years. academicmedicaleducation.com…
39
254
13
905
19,036
Wow. This explains a lot of the anecdotal reports on glp1 and autoimmune or auto inflammatory disease improvements.
Mice that can't make GLP-1 and GLP-2 in their intestines look healthy. Switch on their T cells, and 3 of 12 had to be euthanized by day 5. GLP-1 is the gut hormone behind semaglutide and the new weight loss drugs. So most people file it under appetite and blood sugar. A new study in Cell Reports Medicine from @DanielJDrucker lab at Mount Sinai Hospital in Toronto suggests your gut uses these hormones for something else entirely: protecting itself from your own immune system. Here is how the experiment worked. The team used three kinds of male mice, 12 to 16 weeks old. One group lacked the GLP-1 receptor, the docking site GLP-1 binds to. One lacked the GLP-2 receptor. A third group had the gene for both hormones (proglucagon) deleted only in the intestine, so the gut could no longer make either one. Each group was compared with normal littermates. Then they triggered a controlled immune injury. A single injection of an anti-CD3 antibody activates T cells (immune cells that coordinate attacks) throughout the body. One side effect is enteropathy, meaning the lining of the small intestine gets damaged. In healthy mice this resolves in about 4 to 5 days. To follow the results, it helps to know how that lining is built. It is folded into finger-like projections called villi, which absorb nutrients. At the base of the villi sit small pockets called crypts. Stem cells inside the crypts keep dividing to replace the lining, which renews itself every few days. Paneth cells live there too. They release antimicrobial proteins and support those stem cells. So when you see crypt loss below, it means the renewal pockets are being destroyed. That slows repair of the gut lining. Why does this design matter? Mice with gut-specific proglucagon deletion have normal gut growth and normal metabolic responses, including after weight loss surgery. By that standard these hormones looked optional. This model asks whether they matter under stress, and that is where the answer changed. First, the gut senses the immune activation. In normal mice, plasma GLP-1 rose within 3 hours of the injection and stayed elevated for 24 hours. Giving the antibody by mouth, which doesn't activate T cells body wide, did nothing. So the gut's hormone-secreting cells respond to systemic inflammation, not to the antibody itself. What they found: • Mice without gut-made GLP-1 and GLP-2 recovered more slowly. They started regaining weight on day 5, a day later than normal mice. In that group, 3 of 12 kept losing weight and had to be euthanized. • Mice that couldn't respond to GLP-2 had more gut damage overall, mostly from losing Paneth cells, the gut's defense and support cells (p = 0.0004, 10 to 12 mice). • Mice that couldn't respond to GLP-1 had far more inflammation in the lower small intestine. That meant more neutrophils, the immune system's first responders, and higher levels of the chemical signals that summon them. • A GLP-2 drug called teduglutide, at one fifth of the usual dose, partly rebuilt the lost crypts and calmed inflammation in mice that couldn't make the hormones. • Semaglutide, the GLP-1 drug, at a dose too low to cause extra weight loss, also partly restored the crypts and reduced damage. • Giving both drugs together brought crypt numbers and the damage score back to the level of normal mice. The two hormones did different jobs. What is the mechanism? First, GLP-1 appears to work on the inflammation side. The knockouts for its receptor had more neutrophils and more inflammatory signals, but crypt loss was not different. The authors point to earlier work showing GLP-1 acts on immune cells that sit inside the gut lining. Second, GLP-2 appears to work on the rebuilding side. Mice lacking its receptor had shorter villi, fewer dividing cells in the crypts, and more Paneth cell loss, but inflammation was similar. GLP-2 receptors are mostly absent from immune cells. The authors propose it acts through supporting cells in the gut wall and by restoring the barrier. Third, losing the whole gut supply hit both at once. Those mice had more inflammation and slower rebuilding, plus higher leakage of a tracer dye from the gut and more bacterial endotoxin in the blood. Think of it like a sprinkler system. The building runs fine for years without it. You only find out what it does when something catches fire. There was one puzzle. Teduglutide cut inflammation and damage but did not change the leakage or endotoxin measures. So the rescue was real but partial, and I wouldn't read it as a fully restored barrier. Limitations matter here. This is a mouse study in young, healthy males over 3 to 5 days. It says nothing about sex differences, aging, obesity, or diabetes, which the authors flag as the next experiments. Anti-CD3 injury is an acute model. It is not Crohn's disease or ulcerative colitis, which are chronic and have different drivers. The authors note the story is context dependent: GLP-1 receptor signaling did not change disease severity in a graft versus host disease model, and GLP-2 results there are mixed. The gut-specific deletion removes every proglucagon-derived peptide, not just GLP-1 and GLP-2. Oxyntomodulin and glicentin could contribute, and the study can't separate them. The drug doses were deliberately low. That supports the idea that low doses can work, but it also means higher doses were not tested. Control groups given the inert antibody were small, often 2 to 4 mice. What does this mean for people? The clinical hints are suggestive, not proof. A pilot trial of teduglutide in 100 people with Crohn's showed trends toward better response and remission. A meta-analysis of 11 studies with 16,242 people with inflammatory bowel disease found lower surgery and hospitalization rates in those on GLP-1 drugs. These are associations from observational data. People who get GLP-1 drugs differ from those who don't, so the direction of cause is unclear. Phase 3 trials of tirzepatide in Crohn's and ulcerative colitis are underway. My inference: if gut hormones are part of the body's emergency response to immune injury, then low or blunted signaling could make some people more vulnerable to gut damage. This study did not test that in humans. GLP-1 may be best known for what it does to appetite. In the gut, it may matter more as part of a repair crew that only shows up when the immune system goes too far.
1
20
845
Cerises 🇨🇵 retweeted
Presentations on November 18th will focus on pathogen persistence in Infection-Associated Chronic Disease, next-generation diagnostic tests to detect persistence, and innovative treatments that support immune function.
2
15
45
1,563